Swiss National Bank Grows Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Swiss National Bank increased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 0.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 187,000 shares of the biopharmaceutical company’s stock after acquiring an additional 1,500 shares during the quarter. Swiss National Bank owned about 0.18% of Intra-Cellular Therapies worth $15,618,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Atria Investments Inc boosted its holdings in shares of Intra-Cellular Therapies by 41.1% during the 3rd quarter. Atria Investments Inc now owns 5,137 shares of the biopharmaceutical company’s stock valued at $376,000 after purchasing an additional 1,497 shares during the last quarter. KBC Group NV lifted its position in shares of Intra-Cellular Therapies by 17.3% in the third quarter. KBC Group NV now owns 2,864 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 423 shares in the last quarter. CIBC Asset Management Inc bought a new position in Intra-Cellular Therapies during the third quarter valued at approximately $205,000. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Intra-Cellular Therapies during the 3rd quarter valued at approximately $2,436,000. Finally, Avior Wealth Management LLC increased its stake in Intra-Cellular Therapies by 3.0% in the 3rd quarter. Avior Wealth Management LLC now owns 4,473 shares of the biopharmaceutical company’s stock worth $327,000 after acquiring an additional 131 shares during the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ITCI has been the subject of a number of research reports. Piper Sandler reiterated a “neutral” rating and set a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Mizuho downgraded shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Ten analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Intra-Cellular Therapies has a consensus rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Price Performance

Intra-Cellular Therapies stock opened at $131.53 on Thursday. The stock has a market cap of $13.99 billion, a price-to-earnings ratio of -151.18 and a beta of 0.69. The firm has a 50-day moving average of $126.89 and a two-hundred day moving average of $96.77. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.57.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.